Burashnikov Alexander, Di Diego José M, Sicouri Serge, Ferreiro Marcela, Carlsson Leif, Antzelevitch Charles
Masonic Medical Research Laboratory, Utica, New York 13501, USA.
Heart Rhythm. 2008 Dec;5(12):1735-42. doi: 10.1016/j.hrthm.2008.09.015. Epub 2008 Sep 16.
Although amiodarone is one of the most effective pharmacologic agents used in clinical management of atrial fibrillation (AF), little is known about its differential effects in atrial and ventricular myocardium.
This study sought to compare the electrophysiological effects of chronic amiodarone in atria and ventricles.
We compared the electrophysiological characteristics of coronary-perfused atrial and ventricular wedge preparations isolated from untreated and chronic amiodarone-treated dogs (amiodarone, 40 mg/kg/day for 6 weeks, n = 12).
Chronic amiodarone prolonged action potential duration (APD(90)) predominantly in atria compared to ventricles and prolonged the effective refractory period (ERP) more than APD(90) in both ventricular and atrial preparations (particularly in the latter) due to the development of postrepolarization refractoriness. Amiodarone reduced dispersion of APD(90) in both atria and ventricles. Although the maximum rate of increase of the action potential upstroke (V(max)) was significantly lower in both atria and ventricles of amiodarone-treated hearts versus untreated controls, the reduction of V(max) was much more pronounced in atria. Amiodarone prolonged P-wave duration more significantly than QRS duration, reflecting greater slowing of conduction in atria versus ventricles. These atrioventricular distinctions were significantly accentuated at faster activation rates. Persistent acetylcholine-mediated AF could be induced in only 1 of 6 atria from amiodarone-treated versus 10 of 10 untreated dogs.
Our results indicate that under the conditions studied, chronic amiodarone has potent atrial-predominant effects to depress sodium channel-mediated parameters and that this action of the drug is greatly potentiated by its ability to prolong APD predominantly in the atria, thus contributing to its effectiveness to suppress AF.
尽管胺碘酮是临床治疗心房颤动(AF)最有效的药物之一,但对其在心房和心室心肌中的差异作用知之甚少。
本研究旨在比较慢性胺碘酮对心房和心室的电生理作用。
我们比较了从未经治疗和慢性胺碘酮治疗的犬(胺碘酮,40mg/kg/天,共6周,n = 12)分离出的冠状动脉灌注心房和心室楔形标本的电生理特性。
与心室相比,慢性胺碘酮主要延长心房的动作电位时程(APD(90)),并且由于复极后不应期的出现,在心室和心房标本中均使有效不应期(ERP)延长超过APD(90)(尤其是在后者)。胺碘酮减少了心房和心室中APD(90)的离散度。尽管胺碘酮治疗的心脏的心房和心室中动作电位上升的最大速率(V(max))均显著低于未治疗的对照组,但V(max)的降低在心房中更为明显。胺碘酮延长P波时程比QRS时程更显著,反映出心房传导减慢比心室更明显。这些房室差异在更快的激活速率下显著加剧。在胺碘酮治疗的犬的6个心房中,只有1个能诱发持续性乙酰胆碱介导的AF,而未治疗的犬的10个心房中有10个能诱发。
我们的结果表明,在所研究的条件下,慢性胺碘酮对钠通道介导的参数具有主要的心房优势抑制作用,并且该药物的这种作用因其主要延长心房APD的能力而大大增强,从而有助于其抑制AF的有效性。